Preterm birth (PTB) is one of the most common complications during pregnancy and it primarily accounts for neonatal mortality and numerous morbidities including long-term sequelae including cerebral palsy and developmental disability. The most effective treatment of PTB is prediction and prevention of its risks. Risk factors of PTB include history of PTB, short cervical length (CL), multiple pregnancies, ethnicity, smoking, uterine anomaly and history of curettage or cervical conization. Among these risk factors, history of PTB, and short CL are the most important predictive factors. Progesterone supplement therapy is one of the few proven effective methods to prevent PTB in women with history of spontaneous PTB and in women with short CL. There are 2 types of progesterone therapy currently used for prevention of PTB: weekly intramuscular injection of 17-alpha hydroxyprogesterone caproate and daily administration of natural micronized progesterone vaginal gel, vaginal suppository, or oral capsule. However, the efficacy of progesterone therapy to prevent PTB may vary depending on the administration route, form, dose of progesterone and indications for the treatment. This review aims to summarize the efficacy and safety of progesterone supplement therapy on prevention of PTB according to different indication, type, route, and dose of progesterone, based on the results of recent randomized trials and meta-analysis.

Keywords: Preterm birth; Progesterone; Prevention; 17-alpha-hydroxy-progesterone caproate
inhibits prostaglandin synthesis and inflammation [9].

Studies prior to 1990’s displayed contradictory results, making it difficult to draw a clear conclusion on the effect of progesterone in prevention of PTB. In 2003, however, 2 randomized, double-blind, placebo-controlled trials demonstrated that progesterone supplement therapy can prevent PTB in women with history of PTB [3,4]. Many following studies were carried out to add evidences about prevention of PTB through progesterone supplement therapy, and now the American Congress of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) recommend the usage of progesterone to prevent PTB in certain pregnant women — those with history of spontaneous PTB, such as preterm labor and premature rupture of membranes, and those with short CL during the midtrimester [10,11].

This review aims to summarize the efficacy and safety of progesterone supplement therapy on prevention of PTB according to different indication, type, route, and dose, based on the results of recent randomized trials and meta-analysis. Published literature on prevention of PTB with progesterone therapy was searched from PubMed and Google Scholar combining the terms “progesterone,” “prevention,” or “preterm birth.” All randomized trials that evaluated the efficacy of progesterone supplement therapy on prevention of PTB since 2003 were reviewed in this article.

Type, routes, dose, and interval of administration

Progesterone used for prevention of PTB is divided into 2 types: 17-alpha hydroxyprogesterone caproate (17α-OHPC) and natural micronized progesterone. Administration routes, dose and interval of the 2 types of progesterone commonly used in the randomized trials are summarized in Table 1.

The 17α-OHPC is a synthetic derivative of 17 hydroxyprogesterone. It is inactivated when orally administered, thus it is injected intramuscularly. The half-life of 17α-OHPC is 7.8 days [9], and therefore it is usually administered once a week to maintain serum concentration. Weekly intramuscular injection of 250 mg of 17α-OHPC was effective in preventing PTB in pregnant women with history of PTB [12,13]. In the other trials, higher dose or shorter interval was used in women with short CL, twin pregnancy, and after inhibition of preterm labor [14-17]. However, none these studies proved the efficacy of 17α-OHPC in preventing PTB in these subsets of patients.

Micronized progesterone, a natural progesterone, is similar to that produced in corpus luteum and placenta. Micronized progesterone can be utilized as oral capsule, vaginal gel or vaginal suppository, and all of them are self-administered. When it is orally administered, it is metabolized in the liver and loses its potency, entailing irregular blood concentration and more frequent side effects. When administered through vagina, however, it avoids the first-pass effect by the liver, is absorbed quickly, has increased bioavailability, directly affects the uterus, and is maintained in a high concentration in the serum [9,18,19].

Vaginal progesterone gel is administered through a specific applicator and a dose of 90 mg was used in all published studies [20-23]. Vaginal progesterone suppository is inserted in the vagina with clean hands or plastic gloves. The suppository is placed at the vaginal opening first and then pushed approximately 2 inches inside every day before bedtime. A dose of 100 mg was used in trials that targeted pregnant women with history of PTB [24-26], while 200 mg was used in trials of women with short CL [27]. Yet since no study directly compared the efficacy of 100 and 200 mg, there is no explicit evidence on which dosage has greater effect in preventing PTB. Vaginal progesterone suppository was dosed either 200 or 400 mg when used in twin pregnancies [28-31] or as a treatment after inhibition of preterm labor [32-36], but the optimal dose and its efficacy in twin pregnancies and preterm labor requires further evidence.

The beginning time and duration of the progesterone sup-

| Type                  | Route               | Dose (mg) | Interval |
|-----------------------|---------------------|-----------|----------|
| 17α-OHPC              | Intramuscular injection | 250       | Weekly   |
| Natural micronized progesterone | Vaginal suppository      | 100, 200, 400 | Daily   |
|                       | Vaginal gel             | 90        | Daily    |
|                       | Oral capsule             | 200, 400  | Daily    |

17α-OHPC, 17-alpha hydroxyprogesterone caproate.
Table 2. Summary of randomized controlled trials of progesterone supplement therapy for prevention of PTB in women with history of PTB

| Author                  | Year | No. of patients | Treatment period (wk) | Type of progesterone | Treatment period (interval) | Inclusion criteria | Outcomes & results | Other outcomes |
|-------------------------|------|-----------------|-----------------------|----------------------|-----------------------------|-------------------|-------------------|---------------|
| Meis et al. [12]        | 2003 | 310 vs. 153     | From 16–20            | IM 17α-OHPC 250 mg   | Weekly                      | sPTB history (singleton) | PTB <37 wk: 36.3% vs. 54.9% (P<0.001) | ↓LBW, ↓IVH  |
| Saghafi et al. [13]     | 2011 | 50 vs. 50       | From 16 until         | IM 17α-OHPC 250 mg   | Weekly                      | PTB history         | PTB <37 wk: 32% vs. 60% (P=0.020) | ↑mean GAD, ↑birth weight |
| da Fonseca et al. [25]  | 2003 | 72 vs. 70       | From 24 until         | Vaginal suppository 100 mg daily |                      | sPTB history, uterine anomaly, IIOC (singleton) | PTB <37 wk: 13.8% vs. 28.5% (P=0.030) | ↓mean uterine contractation |
| Majhi et al. [26]       | 2009 | 50 vs. 50       | From 20–24            | Vaginal suppository 100 mg daily | Weekly                      | sPTB history (singleton) | PTB <37 wk: 12% vs. 38% (P=0.003) | ↑birth weight |
| Cetingoz et al. [24]    | 2011 | 80 vs. 70       | From 22–24            | Vaginal suppository 100 mg daily | Weekly                      | sPTB history, uterine anomaly >7 cm | PTB <34 wk: 8.8% vs. 24.3% (P=0.010) | ↓NICU admission, ↓PTB <37 and 34 wk in PTB history, ↓PTB <37 wk in twin |
| Azargoon et al. [41]    | 2016 | 50 vs. 50       | From 16–22            | Vaginal suppository 400 mg daily | Weekly                      | sPTB history (singleton) | PTB <33 wk: 35% vs. 68% (P<0.001) | ↑mean GAD, ↑birth weight, ↓LBW, ↓RDS |
| Norman et al. [42]      | 2016 | 610 vs. 618     | From 18–24            | Oral capsule 200 mg daily | Weekly                      | PTB history, short CL, positive fetal fibronectin with PTB risk factors (singleton) | PTB <37 wk: 10.0% vs. 11.3% | No difference in mean GAD and other neonatal and childhood outcome, except for ↓abnormal brain injury on ultrasound |
| O’Brien et al. [22]     | 2007 | 308 vs. 302     | From 18–24            | Oral capsule 200 mg daily | Weekly                      | sPTB history (singleton) | PTB <37 wk: 32% vs. 39.2% (P<0.002) | No difference in mean GAD and NICU stay, ↓low Apgar scores |
| Rai et al. [44]         | 2009 | 74 vs. 74       | From 18–24            | Oral capsule 400 mg daily | Weekly                      | sPTB history (singleton) | PTB <37 wk: 36.3% vs. 57.1% (P<0.130) | No difference in neonatal outcome |
| Glover et al. [45]      | 2011 | 19 vs. 14       | From 16–20            | Oral capsule 200 mg daily | Weekly                      | sPTB history (singleton) | PTB <37 wk: 26.3% vs. 33% (P=0.001) | No difference in neonatal outcome |

PTB, preterm birth; sPTB, spontaneous preterm birth; IM, intramuscular; 17α-OHPC, 17-alpha hydroxyprogesterone caproate; LBW, low birth weight; MH, intraventricular hemorrhage; GAD, gestational age at delivery; IIOC, incompetent internal os of cervix; NICU, neonatal intensive care unit; RDS, respiratory distress syndrome; CI, cervical length.  

*Primary outcome; †A total of 67 twin pregnancies 39 in the progesterone group and 28 in the placebo group were included.*
Implement therapy in the published studies varied depending on the indications and the medication type. The therapy usually began at 16 to 24 weeks of gestation for those who had history of PTB, whereas it began at 18 to 24 weeks of gestation for those with short cervixes, as the CL is measured through transvaginal ultrasound conventionally after midtrimester. The therapy usually lasted until 34 or 36 weeks of gestation or rupture of membranes or delivery, whatever comes first. Yet, there is certainly a lack of research on optimal gestational age for beginning and until when medication should be used.

Summary of previous studies based on the indications

1. History of PTB
The incidence rate of PTB among all pregnant women is approximately 7–11%, but the rate among those with history of PTB increases to 20–50% in subsequent pregnancies [37,38]. In addition, the recurrence rate increases with shorter gestational age at previous PTB and increasing number of previous PTBs [37,39]. Therefore, history of PTB was the major indication in randomized trials studying the efficacy of progesterone supplement therapy in preventing PTB (Table 2).

1) 17α-OHPC
In 2003, Meis et al. [12] published a randomized, double-blind trial, in which pregnant women with history of spontaneous PTB were injected with 250 mg of 17α-OHPC or its placebo every week from 16 to 20 weeks to 36 weeks of gestation. The result of this randomized study showed that the 17α-OHPC treatment group had the lower rates of PTB <37, <35, and <32 weeks of gestation than the placebo group. Interestingly, the 17α-OHPC treatment was only effective in preventing recurrent PTB in women whose previous PTB occurred before 34 weeks of gestation [40]. Another randomized trial by Saghafi et al. [13] also showed that the 17α-OHPC treatment from 16 to 20 weeks to 36 weeks of gestation was associated with a significantly lower rate of PTB <37 weeks of gestation, accompanied by longer gestational age at delivery (GAD) and higher birth weight.

2) Vaginal natural micronized progesterone suppository
In 2003, da Fonseca et al. [25], published the result of a randomized, double-blind trial of vaginal natural micronized progesterone suppository therapy in high-risk population in which over 90% of the subjects had history of PTB. The result of this study showed that daily administration of 100 mg of vaginal progesterone suppository resulted in the significantly lower rates of PTB <37 and <35 weeks of gestation than the placebo. The effect of vaginal natural micronized progesterone suppository therapy on prevention of PTB was supported by subsequent randomized trials [24,26,41]. However, a recent multicenter, randomized, double-blind trial of vaginal progesterone therapy (dOes Progesterone Prophylaxis To pre vent preterm labour IMprove oUtcoMe [OPPTIMUM] study) showed contradictory results [42]. In this trial, 1,228 high-risk women (history of PTB <34 weeks, CL ≤25 mm, or positive fetal fibronectin test with other risk factors for PTB) received 200 mg of vaginal natural micronized progesterone suppository or its placebo daily, from 22 to 24 weeks to 34 weeks of gestation. This study is as far the largest trial of vaginal progesterone treatment for prevention of PTB in women at risk, but it did not show any effect of progesterone treatment on rates of either PTB or neonatal and infant outcome in the whole study group and all subgroup analyses. The authors addressed that although the results showed no overall effect, point estimates of the reduction of the obstetric and neonatal outcome are in the direction of benefit, and further researches are needed to identify specific women who might specifically benefit.

3) Vaginal natural micronized progesterone gel
In a randomized study performed by O’Brien et al. [22], 659 pregnant women with history of spontaneous PTB were administered daily 90 mg of vaginal natural micronized progesterone gel or its placebo. The 2 groups had no significant difference in terms of PTB rate, GAD, and neonatal outcomes. However, in a secondary analysis of women with CL <28 mm, the progesterone gel treatment was associated with a significantly lower rate of PTB <32 weeks of gestation, a lower rate of admission to neonatal intensive care unit (NICU) and shorter hospital days [43].

4) Oral natural micronized progesterone capsule
In a randomized trial conducted by Rai et al. [44], 100 mg of oral natural micronized progesterone capsule twice a day or placebo was used in women with history of spontaneous PTB. The treatment group had lower rates of PTB <37 weeks of gestation and PTB at 28 to 32 weeks of gestation. Contrarily,
Progesterone & preterm birth prevention

Suk-Joo Choi. Progesterone & preterm birth prevention in a randomized trial performed by Glover et al. [45], no difference was noted in the rate of recurrent PTB and neonatal outcome between the 400-mg oral progesterone group and placebo group. However, due to the small number of subjects and various dosages used in the studies, it is difficult to draw a clear conclusion on the effect of oral administration of progesterone therapy on prevention of PTB.

2. Short CL

The most useful method to predict the risk of PTB is the measurement of CL by vaginal ultrasound during midtrimester [46,47]. The risk of PTB is substantially high when CL is <25 mm, and the risk increases as the CL decreases [48-50]. Therefore, short CL was another major indication in randomized trials studying the efficacy of progesterone supplement therapy in preventing PTB (Table 3).

1) 17α-OHPC

In a randomized trial conducted by Winer et al. [14], pregnant women at high-risk for PTB (history of PTB, cervical surgery, uterine malformation, or prenatal diethylstilbestrol exposure) and short CL (<25 mm) (singleton) were randomized into weekly intramuscular injection of 500 mg 17α-OHPC or no treatment. However, the 2 groups were similar in terms of GAD and the rates of PTB <37, <34, and <32 wk.

2) Vaginal natural micronized progesterone suppository

In a study conducted by Fetal Medicine Foundation in United Kingdom, 24,000 low-risk pregnant women were screened for CL during 20 to 25 weeks of gestation, and 413 women were found to have CL <15 mm. Among them, 250 women were randomly assigned into daily vaginal progesterone suppository or placebo [27]. The progesterone group demonstrated a lower rate of PTB <34 wk: 8.9% vs. 16.1% (P=0.020), PTB <32 wk: 20.8% vs. 36.0% (P=0.020), and the risk increases as the CL decreases [48-50]. Therefore, short CL was another major indication in randomized trials studying the efficacy of progesterone supplement therapy in preventing PTB (Table 3).

Table 3. Summary of randomized controlled trials of progesterone supplement therapy for prevention of PTB in women with short CL

| Author          | Year | No. of patients | Inclusion criteria | Type of progesterone | Progesterone dose & interval | Treatment period (wk) | Outcomes & results (progesterone vs. placebo/no treatment) | Other outcomes |
|-----------------|------|-----------------|--------------------|----------------------|-----------------------------|-----------------------|-------------------------------------------------------------|----------------|
| Winer et al.    | 2015 | 51 vs. 54       | High risk for PTB* and short CL (<25 mm) (singleton) | IM 17α-OHPC          | 500 mg weekly               | From 20–31 until 36  | Mean (SD) time until delivery; 76±5 vs. 72±5 day (P=0.480) | No differences in PTB <37, <34, <32 wk |
| Fonseca et al.  | 2007 | 125 vs. 125     | Short CL (<15 mm) (singleton & twin)** | Vaginal suppository   | 200 mg daily                | From 24 until 34     | sPTB <34 wk: 19.2% vs. 34.4% (P=0.020) | No difference in neonatal outcome |
| Hassan et al.   | 2011 | 235 vs. 223     | Short CL (10–20 mm) (singleton) | Vaginal gel           | 90 mg daily                 | From 20–24 until 36  | PTB <32 wk: 8.9% vs. 16.1% (P=0.020) | ↓ RDS, ↓ neonatal composite morbidity |

PTB, preterm birth; CL, cervical length; IM, intramuscular; 17α-OHPC, 17-alpha hydroxyprogesterone caproate; SD, standard deviation; sPTB, spontaneous preterm birth; RDS, respiratory distress syndrome.

*History of PTB or cervical surgery or uterine malformation or prenatal diethylstilbestrol exposure; **Primary outcome; †A total of 24 twin pregnancies (11 in the progesterone group and 13 in the placebo group) were included.
| Author          | Year | No. of patients (progesterone vs. placebo/no treatment) | Inclusion criteria | Type of progesterone | Progesterone dose & interval | Treatment period (wk) | Outcomes & results (progesterone vs. placebo/no treatment) | Other outcomes |
|-----------------|------|--------------------------------------------------------|-------------------|----------------------|----------------------------|----------------------|--------------------------------------------------------------|---------------|
| Rouse et al.    | 2007 | 325 vs. 330                                           | Twin              | IM 17α-OHPC          | 250 mg weekly              | From 16–20 until 35    | PTB or fetal death <35 wk\(^a\): 41.5% vs. 37.3% (\(P>0.050\)) | No differences in PTB <37, <32, <28 wk |
| Briery et al.   | 2009 | 16 vs. 14                                             | Twin              | IM 17α-OHPC          | 250 mg weekly              | From 20–30 until 34    | PTB <35 wk\(^a\): 44% vs. 79% (\(P=0.117\))                 | No differences in mean GAD and neonatal outcome |
| Lim et al.      | 2012 | 336 vs. 335                                           | Twin\(^b\)        | IM 17α-OHPC          | 250 mg weekly              | From 16–20 until 36    | Composite adverse neonatal outcome\(^a\): 16% vs. 12% (\(P>0.050\)) | No differences in PTB <37, <32, <28 wk |
| Awwad et al.    | 2015 | 194 vs. 94                                            | Twin              | IM 17α-OHPC          | 250 mg weekly              | From 16–20 until 36    | PTB <37 wk\(^a\): 61.3% vs. 61.7% (\(P=0.950\))             | ↑ birth weight, ↓ very LBW, ↓ composite neonatal morbidity |
| Senat et al.    | 2013 | 82 vs. 83                                             | Twin & short CL (<25 mm) | IM 17α-OHPC          | 500 mg x 2weekly          | From 24–32 until 36    | Median (IQR) time until delivery\(^a\): 45 (26–62) vs. 51 (36–66) day (\(P<0.050\)) | No differences in PTB <37, <34 wk, ↑ PTB <32 wk |
| Rode et al.     | 2011 | 334 vs. 343                                           | Twin              | Vaginal suppository  | 200 mg daily              | From 20–24 until 34    | PTB <34 wk\(^a\): 15.3% vs. 18.5% (\(P>0.050\))             | No differences in PTB <37, <32, <28 wk |
| Serra et al.    | 2013 | 97 vs. 97 vs. 96\(^c\)                                 | Twin              | Vaginal suppository  | 400 mg, 200 mg daily      | From 20 until 34       | PTB <37 wk\(^a\): 45.4% vs. 49.5% vs. 49.0% (\(P>0.050\)) | No differences in PTB <34 wk, <32 wk, <28 wk, and neonatal outcome |
| El-Refaie et al.| 2016 | 116 vs. 108                                           | Twin & short CL (20–25 mm) | Vaginal suppository  | 400 mg daily              | From 20–24 until 36    | PTB <34 wk\(^a\): 35.3% vs. 52.8% (\(P=0.010\))             | ↑ mean GAD, ↓ PTB <32 wk, ↓ very LBW, ↓ RDS, ↓ ventilator, ↓ neonatal death |
| Brizot et al.   | 2015 | 189 vs. 191                                           | Twin              | Vaginal suppository  | 200 mg daily              | From 18–22 until 34    | Mean (SD) GAD\(^a\): 35.1±3.2 vs. 35.6±2.9 wk (\(P=0.010\)) | No difference in PTB <37 wk, <34 wk, <32 wk, <28 wk, and neonatal outcome |
| Norman et al.   | 2009 | 250 vs. 250                                           | Twin              | Vaginal gel          | 90 mg daily               | From 24 until 34       | PTB or fetal death <34 wk\(^a\): 24.7% vs. 19.4% (\(P=0.160\)) | No difference in maternal and neonatal outcome |
| Wood et al.     | 2012 | 42 vs. 42                                             | Twin              | Vaginal gel          | 90 mg daily               | From 16–21 until 36    | Mean (IQR) GAD\(^a\): 36±3 (2±6) vs. 36±2 (3±0) wk (\(P=0.589\)) | No difference in PTB <37 wk, <35 wk, and neonatal outcome |

PTB, preterm birth; IM, intramuscular; 17α-OHPC, 17-alpha hydroxyprogesterone caproate; GAD, gestational age at delivery; LBW, low birth weight; CL, cervical length; IQR, interquartile range; SD, standard deviation; RDS, respiratory distress syndrome.

\(^a\)Primary outcome; \(^b\)Women with history of sPTB were excluded; \(^c\)Progesterone 400 vs. progesterone 200 vs. placebo.
supplement therapy to those with a short CL. However, routine screening of CL in all low-risk women is still under debate [52-54].

3) Vaginal natural micronized progesterone gel
In the PREGNANT study conducted by Hassan et al. [20], low-risk singleton pregnant women were screened for short CL of 10 to 20 mm and randomized into daily 90 mg of progesterone gel treatment and placebo. The treatment group demonstrated lower rates of PTB <28, <32, and <35 weeks of gestation than the placebo group, as well as the lower rates of neonatal morbidity including RDS, neonate mortality, and very low birth weight (LBW) infants. In a meta-analysis conducted by Romero et al. [55] in 2012, progesterone supplement therapy was found to decrease the rates of PTB <28, <33, and <35 weeks of gestation, along with the improved neonatal outcomes: lower rates of RDS, mortality, very LBW infant, admission to NICU, and use of mechanical ventilator. In terms of maternal and fetal side effects, no significant difference was noted between the progesterone treatment and control groups.

3. Twin pregnancy
Twin pregnancy, compared to singleton pregnancy, entails higher risk of PTB and more instances of short CL [49,56,57]. However, most of the studies so far have revealed that progesterone supplement therapy in twin pregnancies did not significantly reduce the risk of PTB (Table 4). The ACOG and the SMFM concluded that the effectiveness of progesterone supplement therapy in multiple pregnancy lacks sufficient evidence [10,11]. A recent meta-analysis also showed that both intramuscular and vaginal progesterone supplement therapy was not effective in improving perinatal outcomes of twin pregnancies [58].

1) 17α-OHPC
A randomized, double-blind trial was conducted to examine the effect of intramuscular 17α-OHPC 250 mg on the risk of PTB in twin pregnancies by National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units Network [59]. Six hundred fifty-five twin pregnant women were injected with 17α-OHPC 250 mg or its placebo every week. The primary outcome of PTB or fetal death <35 weeks of gestation was similar in the 2 groups. Following randomized trials targeting twin pregnant women also indicated that intramuscular injection of 17α-OHPC did not reduce the PTB rate or improve neonatal outcomes [60-62]. A higher dose of 17α-OHPC (500 mg twice a week) was used in a randomized trial that targeted twin pregnant women with CL <25 mm [15]. However, the period from randomization to delivery and the rates of PTB <37 and <32 weeks of gestation were not significantly reduced by the higher dose of progesterone treatment, while the rate of PTB <32 weeks of gestation was rather higher in the treatment group than the control group.

2) Vaginal natural micronized progesterone suppository
Similar to 17α-OHPC, 200 mg of vaginal natural micronized progesterone suppository was proven ineffective in prevention of PTB in twin pregnancies [28,30]. In the study by Serra et al. [31], subjects were divided into 200 and 400 mg of vaginal progesterone and placebo group. However, the rates of PTB <37, <34, <32, and <28 weeks of gestation was not reduced by either 200 or 400 mg of progesterone therapy. Aboulghar et al. [63] randomized 306 women with singleton and twin pregnancies conceived by in vitro fertilization into 400 mg of vaginal natural micronized progesterone suppository or placebo. However, the rates of PTB <34 and <37 weeks of gestation were not significantly different between the 2 groups. Interestingly, the secondary analysis showed that the progesterone treatment lowered the rate of PTB <37 weeks of gestation in singleton pregnancies, while the treatment did not lower the rates of PTB <34 and <37 weeks of gestation in twin pregnancies. On the other hand, in a randomized trial that enrolled twin pregnant women with CL of 20 to 25 mm, 400 mg of natural micronized progesterone vaginal suppository therapy was associated with lower rates of PTB <34 and <32 weeks of gestation, along with longer GAD and decreased rates of very LBW infant, neonatal RDS, mortality, and use of mechanical ventilators [29].

3) Vaginal natural micronized progesterone gel
According to the Study of Progesterone for the Prevention of Preterm Birth in Twins (STOPPIT) trial in 2009, daily vaginal progesterone gel supplement treatment did not prevent PTB in twin pregnancies [21]. Five hundred twin pregnant women were assigned to either 90 mg vaginal progesterone gel treatment or placebo, but no difference was noted between the 2 groups in terms of occurrence of stillbirth or PTB <34 weeks of gestation. In a randomized trial conducted by Wood et al. [23], daily vaginal progesterone gel supplement therapy did
Table 5. Summary of randomized controlled trials of progesterone supplement therapy for prevention of PTB in women with preterm labor or preterm premature rupture of membranes

| Author                  | Year | No. of patients (progesterone vs. placebo/no treatment) | Inclusion criteria | Objective of progesterone treatment | Type of progesterone | Progesterone dose & interval | Outcomes & results (progesterone vs. placebo/no treatment) | Other outcomes                  |
|-------------------------|------|---------------------------------------------------------|-------------------|-------------------------------------|----------------------|-----------------------------|----------------------------------------------------------------|---------------------------------|
| Facchinetti et al. [17] | 2007 | 30 vs. 30                                              | PTL at 25–34 wk (singleton) | Maintenance therapy after acute tocolysis | IM 17α-OHPC         | 341 mg biweekly              | Mean (SD) shortening of CL: at day 7 (0.83±1.74 vs. 2.37±2.0 mm [P=0.002], at day 21 (2.40±2.46 vs. 4.60±2.73 mm [P=0.002]) | ↓ PTB <37 wk, birth weight          |
| Rozenberg et al. [16]   | 2012 | 94 vs. 94                                              | PTL at 24–32 wk (singleton) | Maintenance therapy after acute tocolysis | IM 17α-OHPC         | 500 mg semiweekly            | Median (IQR) time until delivery: 64 (42–79) and 67 (46–83) day (P>0.050) | No differences in PTB <37, <34, <32 wk, and neonatal outcome |
| Briery et al. [67]      | 2014 | 22 vs. 23                                              | PTL at 24–34 wk (singleton) | Maintenance therapy after acute tocolysis | IM 17α-OHPC         | 250 mg weekly               | PTB <37 wk: 86.4% vs. 95.7% (P=0.346) | ↓ PTB <34 wk, ↓ IVH, ↓ sepsis                       |
| Lotfalizadeh et al. [68]| 2013 | 37 vs. 37 vs. 36b                                      | PTL at 26–36 wk (singleton) | Maintenance therapy after acute tocolysis | IM 17α-OHPC         | 250 mg weekly 400 mg daily | LBW: 27% vs. 27% vs. 50% (P=0.020) |                                                |
| Briery et al. [70]      | 2011 | 33 vs. 36                                              | PPROM at 20–30 wk (singleton) | Extend latency                       | IM 17α-OHPC         | 250 mg weekly               | Mean (SD) time until delivery: 11.2±7.3 vs. 14.5±10.0 wk (P=0.146) | No differences in GAD and neonatal outcome |
| Combs et al. [86]       | 2015 | 74 vs. 78                                              | PPROM at 23–31 wk (singleton) | Extend latency                       | IM 17α-OHPC         | 250 mg weekly               | Continuation of pregnancy either until 34 wk or until 32–34 wk with documentation of FLM testing: 3% vs. 8% (P=0.180) | No differences in GAD and neonatal outcome |
| Arikan et al. [32]      | 2011 | 43 vs. 40                                              | PTL at 24–34 wk (singleton) | Combination with tocolytics          | Vaginal suppository | 200 mg daily                | Mean (SD) time until delivery: 21.2±16.3 vs. 32.1±17.8 day (P<0.050) | ↑ birth weight, ↓ LBW               |
| Borna and Sahabi [33]   | 2008 | 37 vs. 33                                              | PTL at 24–34 wk (singleton) | Maintenance therapy after acute tocolysis | Vaginal suppository | 400 mg, daily               | Mean (SD) time until delivery: 24.5±27.2 vs. 36.1±17.9 day (P=0.037) | ↑ birth weight, ↓ LBW, ↓ RDS            |
Table 5.  

| Author                  | Year  | No. of patients (progesterone vs. placebo/no treatment) | Inclusion criteria | Objective of progesterone treatment | Type of progesterone dose & interval | Other outcomes |
|-------------------------|-------|--------------------------------------------------------|-------------------|------------------------------------|-------------------------------------|---------------|
| Facchinetti et al.      | 2007  | 200 vs. 200                                            | Singleton         | Maintenance therapy after acute tocolysis | IM 17                                  | No differences in NICU admission until delivery; No differences in PTB <32 wk, latency and neonatal outcome |
| et al. [16]             |       |                                                        |                   |                                    |                                     |               |
| Briery et al.           | 2015  | 126 vs. 132                                            | Singleton         | Maintenance therapy after acute tocolysis | Vaginal suppository 200 mg daily | No differences in PTB <32, <34, <32 wk and neonatal outcome |
|                         |       |                                                        |                   |                                    |                                     |               |
| Sara et al.             | 2014  | 45 vs. 45                                              | Singleton         | Maintenance therapy after acute tocolysis | Oral capsule 200 mg daily | No differences in PTB <37 wk and birth weight |
|                         |       |                                                        |                   |                                    |                                     |               |
| Saleh et al.            | 2012  | 72 vs. 72                                              | Singleton         | Maintenance therapy after acute tocolysis | Vaginal suppository 400 mg daily | No differences in PTB <37 wk and birth weight, ↓ NICU admission, ↓ α, ↑ birth weight, ↓ LBW |
|                         |       |                                                        |                   |                                    |                                     |               |
| Gajaria et al.          | 2015  | 193 vs. 186                                            | Singleton         | Maintenance therapy after acute tocolysis | Vaginal suppository 17α-OHPC 200 mg daily | No differences in PTB <37 wk and birth weight |
|                         |       |                                                        |                   |                                    |                                     |               |
| Martinez et al.         | 2014  | 126 vs. 132                                            | Singleton         | Maintenance therapy after acute tocolysis | Vaginal suppository 17α-OHPC 200 mg daily | No differences in PTB <37 wk and birth weight |
|                         |       |                                                        |                   |                                    |                                     |               |
| Palacio et al.          | 2015  | 45 vs. 45                                              | Singleton         | Maintenance therapy after acute tocolysis | Vaginal suppository 17α-OHPC 200 mg daily | No differences in PTB <37 wk and birth weight |
|                         |       |                                                        |                   |                                    |                                     |               |
| Arikan et al.           | 2011  | 200 vs. 200                                            | Singleton         | Maintenance therapy after acute tocolysis | Vaginal suppository 500 mg daily | No differences in PTB <37 wk and birth weight |
|                         |       |                                                        |                   |                                    |                                     |               |
| Rebecchi et al.         | 2014  | 200 vs. 200                                            | Singleton         | Maintenance therapy after acute tocolysis | Vaginal suppository 17α-OHPC 200 mg daily | No differences in PTB <37 wk and birth weight |
|                         |       |                                                        |                   |                                    |                                     |               |
| Ceballos et al.         | 2015  | 200 vs. 200                                            | Singleton         | Maintenance therapy after acute tocolysis | Vaginal suppository 17α-OHPC 200 mg daily | No differences in PTB <37 wk and birth weight |
|                         |       |                                                        |                   |                                    |                                     |               |
| Palacio et al.          | 2016  | 250 vs. 250                                            | Singleton         | Maintenance therapy after acute tocolysis | Vaginal suppository 17α-OHPC 200 mg daily | No differences in PTB <37 wk and birth weight |
|                         |       |                                                        |                   |                                    |                                     |               |
| Palacio et al.          | 2017  | 250 vs. 250                                            | Singleton         | Maintenance therapy after acute tocolysis | Vaginal suppository 17α-OHPC 200 mg daily | No differences in PTB <37 wk and birth weight |
|                         |       |                                                        |                   |                                    |                                     |               |
| Palacio et al.          | 2018  | 250 vs. 250                                            | Singleton         | Maintenance therapy after acute tocolysis | Vaginal suppository 17α-OHPC 200 mg daily | No differences in PTB <37 wk and birth weight |
|                         |       |                                                        |                   |                                    |                                     |               |

Not extend the gestational age, reduce the PTB rate, or improve the neonatal outcome. However, a recent systematic review and meta-analysis of individual patient data from randomized trials comparing vaginal progesterone therapy with placebo/no treatment in women with a twin gestation and a short CL showed that vaginal progesterone therapy was associated with a significant decrease in the rates of PTB <35, <34, <32, and <30 weeks of gestation and neonatal mortality and morbidity [64].

4. Preterm labor and premature rupture of membranes

As it is already known that progesterone can prevent the shortening of the cervix and inhibit inflammation [65,66], use of progesterone in women with preterm labor or premature rupture of membranes has been another subject of progesterone research (Table 5).

1) 17α-OHPC

In a randomized trial conducted by Facchinetti et al. [17], pregnant women with preterm labor at 25–34 weeks of gestation were treated with tocolytic agents and then randomized into injection of 17α-OHPC twice a week or no treatment. As a result, the treatment group demonstrated less shortening of the cervix, reduction in the PTB <37 weeks of gestation, and larger neonatal birth weight compared to the no treatment group. A randomized study performed by Rozenberg et al. [16], however, demonstrated no difference in interval from randomization until delivery, the rates of PTB <32, <34, and <37 weeks of gestation, and neonatal outcomes between the maintenance 17α-OHPC treatment (500 mg once in 2 weeks) group and no treatment group.

In another randomized study done by Briery et al. [67], weekly 250 mg of 17α-OHPC or placebo was injected as maintenance therapy in women with preterm labor at 24–34 weeks of gestation. The rate of PTB <37 weeks of gestation was not significantly different between the 2 groups, while the rates of PTB <34 weeks of gestation, neonatal IVH, and sepsis were significantly lower in the treatment group. In addition, Lotfalizadeh et al. [68] conducted a randomized trial in which the subjects were divided into three groups — a group treated with weekly 250 mg of 17α-OHPC, a group
treated with daily 400 mg of vaginal natural micronized pro- 
gesterone suppository, and a placebo group. The result of this 
trial showed that the 17α-OHPC and vaginal progesterone 
groups had a significantly lower incidence of LBW infant than 
the placebo group. Furthermore, a meta-analysis performed 
by Saccone et al. [69] showed that 17α-OHPC maintenance 
therapy after initial tocolytics therapy did not reduce the PTB 
rate, but it extended the GAD and increase neonate birth 
weight. The only randomized study that implemented pro-
gesterone supplement therapy in premature rupture of mem-
branes revealed that an injection of 250 mg of 17α-OHPC ev-
every week did not extend the interval from randomization until 
delivery, nor improve neonate outcomes [70].

2) Vaginal natural micronized progesterone suppository
In randomized trials that used daily vaginal natural micronized 
progesterone suppository, either 200 or 400 mg, resulted in a 
longer interval from randomization to delivery, an increase in 
the GAD, an increase in neonate birth weight, and a decrease 
in the LBW infants [32-34]. In a meta-analysis performed by Su-
hag et al. [71], vaginal progesterone supplement therapy was 
associated with a lower rate of PTB, a longer GAD, and a lower 
rates of neonate sepsis. However, 2 large multicenter, random-
ized, double-blind, placebo-controlled trial randomized trials 
[35,36] showed that the maintenance treatment of 200 mg of 
daily vaginal progesterone suppository in women after an epi-
sode of arrested preterm labor did not significantly reduce the 
rates of PTB <37 and <34 weeks of gestation.

3) Oral natural micronized progesterone capsule
According to a randomized trial that compared the mainte-
nance therapy with daily 200 mg of natural micronized pro-
gesterone oral capsule and placebo after inhibition of preterm 
labor, the treatment group had a longer interval from ran-
donization to delivery, a lower rate of PTB <37 weeks of ges-
tation, a higher neonatal birth weight, and a lower incidence 
of LBW infants than the placebo group [72].

17OHCP intramuscular injection 
versus vaginal natural micronized 
progesterone
A great number of previously mentioned studies, along with 
the recommendation or guidelines from various societies and 
associations, have validated that progesterone supplement 
therapy can effectively prevent PTB in women with history of 
PTB and in women with short CL. However, it has not been 
fully elucidated whether which progesterone therapy is better 
with regard to the efficacy of preventing PTB, cost-effectiv-
erness, or side effects. In order to compare the preventative 
effects of 2 different regimens of progesterone therapy, Maher 
et al. [73] conducted a randomized 502 singleton pregnant 
women with history of PTB into weekly intramuscular injec-
tion of 250 mg of 17α-OHPC or daily vaginal administration 
of 90 mg of micronized progesterone gel. The vaginal proges-
terone group had significantly lower rates of PTB <34 weeks 
of gestation, PTB at 28 to 32 weeks of gestation, and a lower 
rates of side effects. However, randomized trials comparing 
daily vaginal progesterone administration and weekly intra-
muscular injection of 250 mg of 17α-OHPC in singleton preg-
nant women with history of PTB or short CL did not show 
any significant differences in the rate of PTB <37 weeks of 
gestation, mean GAD, and neonate outcomes between the 2 
groups [74-76]. A recent systematic review and meta-analysis 
showed that women who received vaginal progesterone had 
significantly lower rates of PTB <34 and <32 weeks of gesta-
tion, a lower rate of adverse drug reactions and a lower rate 
of NICU admission compared with women who received 
17α-OHPC [77]. However, only three trials were included 
in this meta-analysis and different type and dose of vaginal 
progesterone was used in each trial, therefore the quality of 
evidence was not sufficient to conclude which type of proges-
terone is more beneficial.

Currently, the Preterm Birth Committee of Korean Society 
of Maternal Fetal Medicine is conducting “A multicenter, 
randomized, open-label, investigator-initiated trial of vaginal 
compared with intramuscular progesterone for prevention of 
PTB in high-risk pregnant women: VICTORIA study”. In this 
trial, 360 pregnant women with history of PTB and/or short 
CL will be recruited in 24 medical centers nationwide. The 
study will compare the efficacy and safety of 2 regimens of 
progesterone supplement therapy — weekly intramuscular 
injection of 250 mg of 17α-OHPC and daily vaginal adminis-
tration of 200 mg of micronized progesterone.

Maternal-fetal safety and side effects
It has been reported that the usage of progesterone during
the first trimester of pregnancy can lead to masculinization of a female fetus, congenital heart and brain malformations [78]. Yet, in large-scale studies, a clear relationship between progesterone and fetal anomalies has not been elucidated [79,80]. The Food and Drug Administration (FDA) classified natural micronized progesterone medications as category B for pregnancy [78]. A study from NICHD, which used 17α-OHPC, demonstrated no difference between the progesterone-treated and the control groups in terms of miscarriage and stillbirth [12]. An observational follow up study after 30 to 64 months also reported no significant difference in the long-term infant outcomes [81]. In 2011, FDA approved Makena® (17α-OHPC; Hospira, Inc., McPherson, KS, USA) for reduction of PTB in women with history of PTB [82].

Progesterone may entail various systemic side effects such as mood swings, headache, dyspepsia, abdominal pain, constipation, diarrhea, nausea, vomiting, depression, loss of libido, dyspareunia, drowsiness, breast pain, urinary frequency, fatigue, dizziness, genital itching, back pain, fever, flu-like symptoms, and sleep disorders [9]. The synthetic progesterone, 17α-OHPC, has lower rates of these side effects than the natural micronized progesterone [9]. Yet, vaginal administration of micronized progesterone can help avoiding metabolism by the liver, thereby markedly reducing the risk of these side effects [19,83,84]. The majority of the side effects of 17α-OHPC included pain, edema, redness, itching, and bruise, which were all related to the injection, while some studies noted instances of systemic symptoms such as nausea and vomiting [12]. No systemic side effects appeared in trials that used natural micronized progesterone, with the major side effect being an increase in vaginal secretions [25,26,55]. A recent meta-analysis on the safety of progesterone treatment for the prevention of PTB has revealed that progesterone treatment to women at risk for PTB did not negatively affect neonatal mortality in single or multiple pregnancies regardless of the route of administration [85].

Summary

Progesterone supplement therapy is effective in prevention of PTB. However, its efficacy varies depending on the indication and type, administration route, and dose of progesterone. For singleton pregnant women with history of spontaneous PTB, including preterm labor and premature rupture of membranes, weekly injection of 250 mg of 17α-OHPC, as well as daily administration of vaginal micronized progesterone suppository (100 or 200 mg) are effective in preventing recurrent PTB, but the preventative effects of vaginal progesterone gel or oral progesterone capsules currently lack evidence. For singleton pregnant women with CL <25 mm during midtrimester, daily administration of vaginal micronized progesterone suppository (100 or 200 mg) or gel (90 mg every day) is effective in preventing PTB, but the preventative effect of 17α-OHPC therapy lack evidence. In women with twin pregnancy, an injection of 17α-OHPC nor an administration of vaginal micronized progesterone suppository or gel could prevent PTB. Yet, for twin pregnant women with short CL, vaginal progesterone supplement therapy may be effective for reducing the rate of PTB and improving the neonatal outcome. As a maintenance therapy after the inhibition of preterm labor, 17α-OHPC cannot prevent PTB but can extend the gestational age and increase the birth weight. Both vaginal and oral micronized progesterone treatment can prevent PTB <37 weeks of gestation, extend the gestational age, and increase the birth weight. Yet the exact role of progesterone as a maintenance therapy after the inhibition of preterm labor remains much to be discovered. In cases of premature rupture of membranes, there lacks evidence on the effect of progesterone supplement therapy in preventing PTB. The progesterone supplement therapy generally begins at 16 to 24 weeks of gestation and ends at 34 to 36 weeks of gestation. No evidence currently exists on which progesterone supplement therapy can maximize the preventative effects while minimizing the side effects. Therefore, further researches are required to uncover the optimal type, dose and duration of progesterone supplement therapy depending on various indications of treatment.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

Acknowledgements

This study was supported by the Korea Health Technology R&D Project through the Korea Health Industry Development
Institute, funded by the Ministry of Health and Welfare, Republic of Korea (grant number: HI14C0306).

References

1. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 2012;379:2162-72.

2. Korean Statistical Information Service. Birth statistics [Internet]. Daejeon: Statistics Korea; 2016 [cited 2016 Aug 24]. Available from: http://kosis.kr/statHtml/statHtml.do?orgId=101&tblId=DT_1B81A15&vw_cd=MT_ZTITLE&list_id=A21_7&seqNo=&lang_mode=ko&language=kor&obj_var_id=&itm_id=&conn_path=E1.

3. Natarajan G, Shankaran S. Short- and long-term outcomes of moderate and late preterm infants. Am J Perinatol 2016;33:305-17.

4. Harrison MS, Goldenberg RL. Global burden of prematurity. Semin Fetal Neonatal Med 2016;21:74-9.

5. Khan KS, Honest H. Risk screening for spontaneous preterm labour. Best Pract Res Clin Obstet Gynaecol 2007;21:821-30.

6. Newnham JP, Dickinson JE, Hart RJ, Pennell CE, Arrese CA, Keelan JA. Strategies to prevent preterm birth. Front Immunol 2014;5:584.

7. da Fonseca EB, Bittar RE, Damião R, Zugaib M. Prematurity prevention: the role of progesterone. Curr Opin Obstet Gynecol 2009;21:142-7.

8. Romero R, Yeo L, Chaemsithong P, Chaivorapongsa T, Hassan SS. Progesterone to prevent spontaneous preterm birth. Semin Fetal Neonatal Med 2014;19:15-26.

9. How HY, Sibai BM. Progesterone for the prevention of preterm birth: indications, when to initiate, efficacy and safety. Ther Clin Risk Manag 2009;5:55-64.

10. Society for Maternal-Fetal Medicine Publications Committee, with assistance of Vincenzo Berghella. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. Am J Obstet Gynecol 2012;206:376-86.

11. Committee on Practice Bulletins—Obstetrics, The American College of Obstetricians and Gynecologists. Practice bulletin no. 130: prediction and prevention of preterm birth. Obstet Gynecol 2012;120:964-73.

12. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379-85.

13. Saghaﬁ N, Khadem N, Mohajeri T, Shakeri MT. Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery. J Obstet Gynaecol Res 2011;37:1342-5.

14. Winer N, Bretelle F, Senat MV, Bohec C, Deruelle P, Perrotin F, et al. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial. Am J Obstet Gynecol 2015;212:485.e1-10.

15. Senat MV, Porcher R, Winer N, Vayssiére C, Deruelle P, Capelle M, et al. Prevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. Am J Obstet Gynecol 2013;208:194.e1-8.

16. Rozenberg P, Chauveaud A, Deruelle P, Capelle M, Winer N, Desbrière R, et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Am J Obstet Gynecol 2013;206:206.e1-9.

17. Facchinetti F, Paganelli S, Comitini G, Dante G, Volpe A. Cervical length changes during preterm cervical ripening: effects of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 2007;196:453.e1-4.

18. Cicinelli E, Schonauer LM, Galantino P, Matteo MG, Casseretta R, Pinto V. Mechanisms of uterine specificity of vaginal progesterone. Hum Reprod 2000;15 Suppl 1:159-65.

19. Levy T, Yairi Y, Bar-Hava I, Shalev J, Orvieto R, Ben-Rafael Z. Pharmacokinetics of the progesterone-containing vaginal tablet and its use in assisted reproduction. Steroids 2000;65:645-9.

20. Hassan SS, Romero R, Vidyadhari D, Fuese S, Baxter JK, Khandelwal M, et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2011;38:18-31.

21. Norman JE, Mackenzie F, Owen P, Mactier H, Hanretty K,
Cooper S, et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis. Lancet 2009;373:2034-40.

22. O’Brien JM, Adair CD, Lewis DF, Hall DR, Defranco EA, Fusey S, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomised, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007;30:687-96.

23. Wood S, Ross S, Tang S, Miller L, Sauve R, Brant R. Vaginal progesterone to prevent preterm birth in multiple pregnancy: a randomized controlled trial. J Perinat Med 2012;40:593-9.

24. Cetingoz E, Cam C, Sakalli M, Karateke A, Celik C, Sancak A. Progesterone effects on preterm birth in high-risk pregnancies: a randomised placebo-controlled trial. Arch Gynecol Obstet 2011;283:423-9.

25. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomised placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188:419-24.

26. Majhi P, Bagga R, Kalra J, Sharma M. Intravaginal use of natural micronised progesterone to prevent pre-term birth: a randomised trial in India. J Obstet Gynaecol 2009;29:493-8.

27. Fonseca EB, Celic E, Parra M, Singh M, Nicolaides KH; Fetal Medicine Foundation Second Trimester Screening Group. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007;357:462-9.

28. Brizot ML, Hernandez W, Liao AW, Bittar RE, Francisco RP, Krebs VL, et al. Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2015;213:82.e1-9.

29. El-Refaie W, Abdelhafez MS, Badawy A. Vaginal progesterone for prevention of preterm labor in asymptomatic twin pregnancies with sonographic short cervix: a randomized clinical trial of efficacy and safety. Arch Gynecol Obstet 2016;293:61-7.

30. Rode L, Klein K, Nicolaides KH, Krampl-Bettelheim E, Tabor A; PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol 2011;38:272-80.

31. Serra V, Perales A, Meseguer J, Parrilla JJ, Lara C, Bellver J, et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double-blind multicentre trial. BJOG 2013;120:50-7.

32. Arikan I, Barut A, Harmo M, Harmo IM. Effect of progesterone as a tocolytic and in maintenance therapy during preterm labor. Gynecol Obstet Invest 2011;72:269-73.

33. Borja S, Sahabi N. Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Aust N Z J Obstet Gynaecol 2008;48:58-63.

34. Saleh Gargari S, Habibolah M, Zonobi Z, Khani Z, Sarfjoo FS, Kazemi Robati A, et al. Outcome of vaginal progesterone as a tocolytic agent: randomized clinical trial. ISRN Obstet Gynecol 2012;2012:607906.

35. Martinez de Tejada B, Karolinski A, Ocampo MC, Laterra C, Hösl I, Fernández D, et al. Prevention of preterm delivery with vaginal progesterone in women with preterm labour (4P): randomised double-blind placebo-controlled trial. BJOG 2015;122:80-91.

36. Palacio M, Cobo T, Antolín E, Ramirez M, Cabrera F, Mozo de Rosales F, et al. Vaginal progesterone as maintenance treatment after an episode of preterm labour (PROMISE) study: a multicentre, double-blind, randomised, placebo-controlled trial. BJOG 2016;123:1990-9.

37. Iams JD, Berghella V. Care for women with prior preterm birth. Am J Obstet Gynecol 2010;203:89-100.

38. Edlow AG, Srinivas SK, Elovitz MA. Second-trimester loss and subsequent pregnancy outcomes: what is the real risk? Am J Obstet Gynecol 2007;197:581.e1-6.

39. McManemy J, Cooke E, Amon E, Leet T. Recurrence risk for preterm delivery. Am J Obstet Gynecol 2007;196:576.e1-6.

40. Spong CY, Meis PJ, Thom EA, Sibai B, Dombrowski MP, Moawad AH, et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. Am J Obstet Gynecol 2005;193:1127-31.

41. Azargoon A, Ghorbani R, Aslebahar F. Vaginal progesterone on the prevention of preterm birth and neonatal complications in high risk women: a randomized placebo-controlled double-blind study. Int J Reprod Biomed
42. Norman JE, Marlow N, Messow CM, Shennan A, Bennett PR, Thornton S, et al. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. Lancet 2016;387:2106-16.

43. DeFranco EA, O’Brien JM, Adair CD, Lewis DF, Hall DR, Fusey S, et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007;30:697-705.

44. Rai P, Rajaram S, Goel N, Ayalur Gopalakrishnan R, Agarwal R, Mehta S. Oral micronized progesterone for prevention of preterm birth. Int J Gynaecol Obstet 2009;104:40-3.

45. Glover MM, McKenna DS, Downing CM, Smith DB, Croom CS, Sonek JD. A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. Am J Perinatol 2011;28:377-81.

46. Grimes-Dennis J, Berghella V. Cervical length and prediction of preterm delivery. Curr Opin Obstet Gynecol 2007;19:191-5.

47. Iams JD, Goldenberg RL, Meis PJ, Mercer BM, Moawad A, Das A, et al. The length of the cervix and the risk of spontaneous premature delivery. N Engl J Med 1996;334:567-72.

48. Iams JD, Goldenberg RL, Mercer BM, Moawad A, Thom E, Meis PJ, et al. The preterm prediction study: recurrence risk of spontaneous preterm birth. Am J Obstet Gynecol 1998;178:1035-40.

49. Goldenberg RL, Iams JD, Miodownik M, Van Dorsten JP, Thurnau G, Bottoms S, et al. The preterm prediction study: risk factors in twin gestations. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1996;175:1047-53.

50. Guzman ER, Walters C, O’Reilly-Green C, Kinzler WL, Waldron R, Nigam J, et al. Use of cervical ultrasonography in prediction of spontaneous preterm birth in twin gestations. Am J Obstet Gynecol 2000;183:1103-7.

51. Romero R, Nicolaides KH, Conde-Agudelo A, O’Brien JM, Cetingoz E, Da Fonseca E, et al. Vaginal progesterone decreases preterm birth ≤ 34 weeks of gestation in women with a singleton pregnancy and a short cervix: an updated meta-analysis including data from the OPPTIMUM study. Ultrasound Obstet Gynecol 2016;48:308-17.

52. Society for Maternal Fetal Medicine Publications Committee. ACOG Committee Opinion number 419 October 2008 (replaces no. 291, November 2003). Use of progesterone to reduce preterm birth. Obstet Gynecol 2008;112:963-5.

53. Pedretti MK, Kazemier BM, Dickinson JE, Mol BW. Implementing universal cervical length screening in asymptomatic women with singleton pregnancies: challenges and opportunities. Aust N Z J Obstet Gynaecol 2017;57:221-7.

54. Rozenberg P. Universal cervical length screening for singleton pregnancies with no history of preterm delivery, or the inverse of the Pareto principle. BJOG 2017;124:1038-45.

55. Romero R, Nicolaides K, Conde-Agudelo A, Tabor A, O’Brien JM, Cetingoz E, et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and meta-analysis of individual patient data. Am J Obstet Gynecol 2012;206:124.e1-19.

56. Fuchs F, Senat MV. Multiple gestations and preterm birth. Semin Fetal Neonatal Med 2016;21:113-20.

57. Biggio JR, Anderson S. Spontaneous preterm birth in multiples. Clin Obstet Gynecol 2015;58:654-67.

58. Schuit E, Stock S, Rode L, Rouse DJ, Lim AC, Norman JE, et al. Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta-analysis. BJOG 2015;122:27-37.

59. Rouse DJ, Caritis SN, Pecoraro CR, Sciscione A, Thom EA, Spong CY, et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent premature in twins. N Engl J Med 2007;357:454-61.

60. Briery CM, Veillon EW, Klauser CK, Martin RW, Chauhan SP, Magann EF, et al. Progesterone does not prevent preterm births in women with twins. South Med J 2009;102:900-4.

61. Lim AC, Schuit E, Papatsonis D, van Eyck J, Porath MM, van Oirschot CM, et al. Effect of 17-alpha hydroxyprogesterone caproate on cervical length in twin pregnancies. Ultrasound Obstet Gynecol 2012;40:426-30.
62. Awwad J, Usta IM, Ghazeeri G, Yacoub N, Succar J, Hayek S, et al. A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGEST-TWIN): evidence for reduced neonatal morbidity. BJOG 2015;122:71-9.

63. Aboulghar MM, Aboulghar MA, Amin YM, Al-Inany HG, Mansour RT, Serour GI. The use of vaginal natural progesterone for prevention of preterm birth in IVF/ICSI pregnancies. Reprod Biomed Online 2012;25:133-8.

64. Romero R, Conde-Agudelo A, El-Refaie W, Rode L, Brizot ML, Cetingoz E, et al. Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta-analysis of individual patient data. Ultrasound Obstet Gynecol 2017;49:303-14.

65. Hall NR. What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone? Obstet Gynecol Clin North Am 2011;38:235-46, ix-x.

66. Elovitz MA, Mrinalini C. Can medroxyprogesterone acetate alter Toll-like receptor expression in a mouse model of intrauterine inflammation? Am J Obstet Gynecol 2005;193:1149-55.

67. Briery CM, Klauser CK, Martin RW, Magann EF, Chauhan SP, Morrison JC. The use of 17-hydroxyprogesterone in women with arrested preterm labor: a randomized clinical trial. J Matern Fetal Neonatal Med 2014;27:1892-6.

68. Lotfalizadeh M, Ghomian N, Reyhani A. The effects of progesterone therapy on the gestation length and reduction of neonatal complications in patients who had received tocolytic therapy for acute phase of preterm labor. Iran Red Crescent Med J 2013;15:e7947.

69. Saccone G, Suhag A, Berghella V. 17-alpha-hydroxyprogesterone caproate for maintenance tocolysis: a systematic review and metaanalysis of randomized trials. Am J Obstet Gynecol 2015;213:16-22.

70. Briery CM, Veillon EW, Klauser CK, Martin RW, Magann EF, Chauhan SP, et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. Am J Obstet Gynecol 2011;204:54.e1-5.

71. Suhag A, Saccone G, Berghella V. Vaginal progesterone for maintenance tocolysis: a systematic review and metaanalysis of randomized trials. Am J Obstet Gynecol 2015;213:479-87.

72. Choudhary M, Suneja A, Vaid NB, Guleria K, Faridi MM. Maintenance tocolysis with oral micronized progesterone for prevention of preterm birth after arrested preterm labor. Int J Gynaecol Obstet 2014;126:60-3.

73. Maher MA, Abdelaziz A, Ellaihy M, Bazeed MF. Prevention of preterm birth: a randomized trial of vaginal compared with intramuscular progesterone. Acta Obstet Gynecol Scand 2013;92:215-22.

74. Bafghi AS, Bahrami E, Sekhavat L. Comparative study of vaginal versus intramuscular progesterone in the prevention of preterm delivery: a randomized clinical trial. Electron Physician 2015;7:1301-9.

75. Pirjani R, Heidari R, Rahimi-Foroushani A, Bayesh S, Esmailzadeh A. 17-alpha-hydroxyprogesterone caproate versus vaginal progesterone suppository for the prevention of preterm birth in women with a sonographically short cervix: a randomized controlled trial. J Obstet Gynecol Res 2017;43:57-64.

76. Elimian A, Smith K, Williams M, Knudtson E, Goodman JR, Escobedo MB. A randomized controlled trial of intramuscular versus vaginal progesterone for the prevention of recurrent preterm birth. Int J Gynaecol Obstet 2016;134:169-72.

77. Saccone G, Khalifeh A, Elimian A, Bahrami E, Chamann-Ara K, Bahrami MA, et al. Vaginal progesterone vs intramuscular 17α-hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth in singleton gestations: systematic review and meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol 2017;49:315-21.

78. Golub MS, Kaufman FL, Campbell MA, Li LH, Donald JM. “Natural” progesterone: information on fetal effects. Birth Defects Res B Dev Reprod Toxicol 2006;77:455-70.

79. Brent RL. Nongenital malformations following exposure to progestational drugs: the last chapter of an erroneous allegation. Birth Defects Res A Clin Mol Teratol 2005;73:906-18.

80. Raman-Wilms L, Tseng AL, Wighardt S, Einarson TR, Koren G. Fetal genital effects of first-trimester sex hormone exposure: a meta-analysis. Obstet Gynecol 1995;85:141-9.

81. Northen AT, Norman GS, Anderson K, Moseley L, Divito M, Cotroneo M, et al. Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo. Obstet Gynecol 2007;110:865-72.

82. Armstrong J. Unintended consequences—the cost of pre-
venting preterm births after FDA approval of a branded version of 17OHP. N Engl J Med 2011;364:1689-91.
83. Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 1994;62:485-90.
84. Friedler S, Raziel A, Schachter M, Strassburger D, Bukovsky I, Ron-El R. Luteal support with micronized progesterone following in-vitro fertilization using a down-regulation protocol with gonadotrophin-releasing hormone agonist: a comparative study between vaginal and oral administration. Hum Reprod 1999;14:1944-8.
85. Ahn KH, Bae NY, Hong SC, Lee JS, Lee EH, Jee HJ, et al. The safety of progestogen in the prevention of preterm birth: meta-analysis of neonatal mortality. J Perinat Med 2017;45:11-20.
86. Combs CA, Garite TJ, Maurel K, Abril D, Das A, Clewell W, et al. 17-hydroxyprogesterone caproate for preterm rupture of the membranes: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol 2015;213:364.e1-12.